NASDAQ:MREO Mereo BioPharma Group Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. $1.53 +0.12 (+8.51%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$1.25▼$1.6250-Day Range$0.33▼$1.6952-Week Range$0.30▼$3.31Volume7.91 million shsAverage Volume11.87 million shsMarket Capitalization$178.98 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MREO Stock Forecast (MarketRank)Overall MarketRank™1.98 out of 5 starsMedical Sector617th out of 1,411 stocksPharmaceutical Preparations Industry285th out of 672 stocksAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Mereo BioPharma Group has a forecasted upside of 357.5% from its current price of $1.53.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 3 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesMereo BioPharma Group has received 21 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMereo BioPharma Group has received 13 “underperform” votes. (Add your “underperform” vote.)Community SentimentMereo BioPharma Group has received 61.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote “Outperform” if you believe MREO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MREO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by Institutions77.39% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mereo BioPharma Group are expected to grow in the coming year, from ($0.59) to ($0.39) per share.Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mereo BioPharma Group (NASDAQ:MREO)Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.Read More MREO Stock News HeadlinesJune 20, 2022 | finance.yahoo.comMereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes BuyoutJune 8, 2022 | americanbankingnews.comMereo BioPharma Group (NASDAQ:MREO) Price Target Cut to $5.00June 2, 2022 | finance.yahoo.comMereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization PlanJune 2, 2022 | americanbankingnews.comMereo BioPharma Group (NASDAQ:MREO) Downgraded by Zacks Investment ResearchMay 26, 2022 | finance.yahoo.comMereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual MeetingMay 17, 2022 | finance.yahoo.comMereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of DirectorsMay 9, 2022 | seekingalpha.comMereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trialMay 9, 2022 | finance.yahoo.comMereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated EmphysemaMay 6, 2022 | finance.yahoo.comMereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of AlvelestatMay 6, 2022 | finance.yahoo.comMereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of AlvelestatApril 22, 2022 | finance.yahoo.comMEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerApril 6, 2022 | finance.yahoo.comMereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare ConferenceMarch 31, 2022 | finance.yahoo.comMereo BioPharma Reports Full Year 2021 Financial Results and Recent HighlightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MREO CUSIPN/A CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees38Year FoundedN/ACompany Calendar Today6/26/2022Next Earnings (Estimated)6/30/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+357.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.16 Current Ratio7.92 Quick Ratio7.92 Sales & Book Value Annual Sales$50.14 million Price / Sales3.57 Cash Flow$0.16 per share Price / Cash Flow9.74 Book Value$1.03 per share Price / Book1.49Miscellaneous Outstanding Shares116,980,000Free FloatN/AMarket Cap$178.98 million OptionableNot Optionable Beta2.02 Mereo BioPharma Group Frequently Asked Questions Should I buy or sell Mereo BioPharma Group stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mereo BioPharma Group stock. View analyst ratings for Mereo BioPharma Group or view top-rated stocks. What is Mereo BioPharma Group's stock price forecast for 2022? 3 equities research analysts have issued 1 year price targets for Mereo BioPharma Group's shares. Their MREO stock forecasts range from $5.00 to $8.00. On average, they predict Mereo BioPharma Group's share price to reach $7.00 in the next year. This suggests a possible upside of 357.5% from the stock's current price. View analysts' price targets for Mereo BioPharma Group or view top-rated stocks among Wall Street analysts. How has Mereo BioPharma Group's stock performed in 2022? Mereo BioPharma Group's stock was trading at $1.60 at the beginning of the year. Since then, MREO shares have decreased by 4.4% and is now trading at $1.53. View the best growth stocks for 2022 here. When is Mereo BioPharma Group's next earnings date? Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Thursday, June 30th 2022. View our earnings forecast for Mereo BioPharma Group. Who are Mereo BioPharma Group's key executives? Mereo BioPharma Group's management team includes the following people: Dr. Denise Scots-Knight Ph.D., Co-Founder, CEO & Exec. Director (Age 63, Pay $880.7k)Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 53)Dr. Alastair MacKinnon M.D., MBBS, Co-Founder and Chief of Portfolio & Pipeline Strategy (Age 52)Dr. John P. Richard M.B.A., MBA, Co-Founder & Chief Bus. Officer (Age 65)Ms. Christine Fox CPA, Chief Financial Officer (Age 41)Dr. John A. Lewicki Ph.D., Chief Scientific Officer (Age 70)Dr. Jackie Parkin, Therapy Area Head of Respiratory EndocrinologyMs. Alexandra Hughes-Wilson, Chief of Patient Access & Commercial Planning (Age 51)Dr. Suba Krishnan, Sr. VP of Clinical Devel.Dr. Fiona Bor, Head of Intellectual Property Who are some of Mereo BioPharma Group's key competitors? Some companies that are related to Mereo BioPharma Group include Kiniksa Pharmaceuticals (KNSA), Avidity Biosciences (RNA), Northwest Biotherapeutics (NWBO), Keros Therapeutics (KROS), Catalyst Pharmaceuticals (CPRX), Theravance Biopharma (TBPH), Ventyx Biosciences (VTYX), MorphoSys (MOR), Emisphere Technologies (EMIS), Pharvaris (PHVS), POINT Biopharma Global (PNT), Nuvalent (NUVL), AnaptysBio (ANAB), Zealand Pharma A/S (ZEAL) and Y-mAbs Therapeutics (YMAB). View all of MREO's competitors. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd). When did Mereo BioPharma Group IPO? (MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. What is Mereo BioPharma Group's stock symbol? Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO." Who are Mereo BioPharma Group's major shareholders? Mereo BioPharma Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (5.19%), Clearline Capital LP (1.11%), BlackRock Inc. (0.64%), Maven Securities LTD (0.47%), Eversept Partners LP (0.32%) and Renaissance Technologies LLC (0.24%). Which major investors are selling Mereo BioPharma Group stock? MREO stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC. Which major investors are buying Mereo BioPharma Group stock? MREO stock was bought by a variety of institutional investors in the last quarter, including Clearline Capital LP, Rock Springs Capital Management LP, BlackRock Inc., Maven Securities LTD, J. Goldman & Co LP, Bank of America Corp DE, Eversept Partners LP, and Renaissance Technologies LLC. How do I buy shares of Mereo BioPharma Group? Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mereo BioPharma Group's stock price today? One share of MREO stock can currently be purchased for approximately $1.53. How much money does Mereo BioPharma Group make? Mereo BioPharma Group (NASDAQ:MREO) has a market capitalization of $178.98 million and generates $50.14 million in revenue each year. How many employees does Mereo BioPharma Group have? Mereo BioPharma Group employs 38 workers across the globe. How can I contact Mereo BioPharma Group? Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The official website for Mereo BioPharma Group is www.mereobiopharma.com. The company can be reached via phone at 44-33-3023-7300 or via email at [email protected]. This page (NASDAQ:MREO) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
